769-P: Efficacy and Safety of GLP1RAs in Liver-Transplanted People with Diabetes-Ad Interim Results of a 24-Month Trial

GLP1 RAs are first line drugs for DM2, due to their effects on glycemic control, cardiorenal protection and weight-loss action. However, consistent data about efficacy and safety in patients with liver transplant (LT) are lacking. Aim: to assess the efficacy and safety of GLP1RAs in people with LT and diabetes in a period of 24 months. Methods: 52 patients with DM and LT, were enrolled: follow up visits were planned 6-12-24 months after starting a GLP1RA-based therapy (dulaglutide or injectable semaglutide), as add on to metformin or insulin. We assessed glycemic control, body weight and composition (with bio-impedance analysis), liver fibrosis and steatosis (with transient elastography). Amylase, lipase levels and concomitant therapies were recorded at all visits. Patients had an e-mail contact to report any adverse events (AE). At the ad interim analysis, all patients enrolled underwent the first follow up visit, 29 patients completed the study. Results: We observed a decrease in blood glucose (BG - 8.0±2.2 to 6.8±1.45 to 7.4±1.7mmol/L) and HbA1c (7.1±0.9 to 6.5±1.0 to 6.4±0.6%), p 3 times the normal values. Of them, all suffered from biliary strictures). At the short-term follow up, we already observed the improvement in BG and HbA1c (p